Suppr超能文献

一种用于丙型肝炎病毒核心抗原的简单且高灵敏度酶免疫测定法的开发。

Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.

作者信息

Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S

机构信息

Diagnostic Division, Tonen Corporation, Ohi-Machi, Iruma-Gun, Saitama 356-8505, Japan.

出版信息

J Clin Microbiol. 1999 Jun;37(6):1802-8. doi: 10.1128/JCM.37.6.1802-1808.1999.

Abstract

A highly sensitive enzyme immunoassay (EIA) for the hepatitis C virus (HCV) core antigen (HCVcAg) was developed, and its performance was compared with that of the AMPLICOR HCV test (Roche Molecular Systems). The developed one-step pretreatment method, 30-min incubation of the specimen with a solution containing three different types of detergents (Triton X-100, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], and sodium dodecyl sulfate), does not require any special device. Because the interfering anti-core antibody in the sample was sufficiently inactivated by the pretreatment, HCVcAg in the sample could be detected. The immunoreactivity on gel filtration was shifted from void fractions to those corresponding to the molecular mass range from 20 to 25 kDa, which is equal to the estimated molecular mass of HCVcAg, after the pretreatment. By the recovery test with HCVcAg-positive serum, the recovery rate was 93.5 to 106. 5%. There was no interference with the EIA by anticoagulants or blood components in the serum. When the cutoff value was tentatively set at 0.5 mU/ml based on the distribution of healthy subjects' sera, the sera of all healthy subjects (n = 125) and patients with hepatitis B (n = 50) were negative. HCVcAg was detected in sera from 57 of 73 individuals (78.1%) with anti-HCV antibody. Similarly, HCV RNA was detected in sera from 59 individuals (80.8%) with the AMPLICOR HCV as the qualitative test (AMPLICOR HCV test) and in sera from 54 individuals (74.0%) by the AMPLICOR HCV Monitor as the quantitative test (AMPLICOR Monitor test). Concentrations of HCVcAg and HCV RNA (measured by the AMPLICOR Monitor test) correlated significantly (r = 0.8, P < 0.001). On seroconversion panels, HCVcAg was detected during the early stage of infection, when anti-HCV antibodies had not been produced. This assay for HCVcAg is simpler than assays for HCV RNA based on gene technology and shows specificity and sensitivity equivalent to those of the AMPLICOR HCV test.

摘要

开发了一种用于丙型肝炎病毒(HCV)核心抗原(HCVcAg)的高灵敏度酶免疫测定(EIA),并将其性能与AMPLICOR HCV检测法(罗氏分子系统公司)进行了比较。所开发的一步预处理方法是将标本与含有三种不同类型去污剂(Triton X - 100、3 - [(3 - 胆酰胺丙基)-二甲基铵基]-1 - 丙烷磺酸盐[CHAPS]和十二烷基硫酸钠)的溶液孵育30分钟,该方法不需要任何特殊设备。由于预处理充分灭活了样品中具有干扰性的抗核心抗体,因此可以检测样品中的HCVcAg。预处理后,凝胶过滤上的免疫反应性从空体积组分转移到对应于20至25 kDa分子量范围的组分,这与HCVcAg的估计分子量相等。通过对HCVcAg阳性血清进行回收率测试,回收率为93.5%至106.5%。血清中的抗凝剂或血液成分对EIA没有干扰。当根据健康受试者血清的分布将临界值初步设定为0.5 mU/ml时,所有健康受试者(n = 125)和乙型肝炎患者(n = 50)的血清均为阴性。在73例抗HCV抗体阳性个体中,有57例(78.1%)的血清检测到HCVcAg。同样,作为定性检测(AMPLICOR HCV检测法),在59例个体(80.8%)的血清中检测到HCV RNA,作为定量检测(AMPLICOR监测检测法),在54例个体(74.0%)的血清中检测到HCV RNA。HCVcAg浓度与HCV RNA浓度(通过AMPLICOR监测检测法测量)显著相关(r = 0.8,P < 0.001)。在血清转换板上,在感染早期,即在尚未产生抗HCV抗体时,就检测到了HCVcAg。这种检测HCVcAg的方法比基于基因技术的HCV RNA检测方法更简单,并且显示出与AMPLICOR HCV检测法相当的特异性和灵敏度。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验